Odyssey Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 19.54 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 936.33M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis...